Table 3 Results of subgroup analyses for studies evaluating the effect of magnesium on serum TG

Total

-

26

-2.06 (-6.35, 2.23)

0.346

99.1

< 0.001

magnesium dose (mg/d)

< 325 mg/d

13

-1.01 (-9.52, 7.49)

0.816

99.3

< 0.001

≥ 325 mg/d

13

-2.94 (-7.31, 1.44)

0.188

89.4

< 0.001

Trial design

Parallel

23

-2.28 (-6.89, 2.33)

0.332

99.2

< 0.001

Cross-over

3

0.40 (-8.49, 9.30)

0.930

82.5

0.003

Intervention duration

< 84 days

8

-0.15 (-4.82, 4.53)

0.278

52.4

0.040

≥ 84 days

18

-2.84 (-7.96, 2.29)

0.951

99.4

< 0.001

Baseline TG (mg/dl)

< 130 mg/dl

13

0.09 (-2.70, 2.88)

0.949

77.4

< 0.001

≥ 130 mg/dl

13

-3.43 (-12.32, 5.46)

0.450

99.3

< 0.001

Health status

Healthy

4

0.13 (-0.07, 0.34)

0.202

0.00

0.475

At risk/disease

22

-2.05 (-8.55, 4.46)

0.538

98.8

< 0.001

Sample size

< 61 persons

13

-0.29 (-3.95, 3.36)

0.876

49.6

0.022

≥ 61 persons

13

-4.20 (-10.11, 1.70)

0.163

99.6

< 0.001

Sex

Female

5

4.85 (-2.52, 12.22)

0.197

82.2

< 0.001

Male

1

-3.87 (-9.18, 1.45)

0.154

-

-

Both

20

-3.57 (-10.28, 3.14)

0.298

98.9

< 0.001

Age

< 50 years

13

-2.52 (-11.35, 6.32)

0.577

99.3

< 0.001

≥ 50 years

13

-1.55 (-4.61, 1.52)

0.323

79.9

< 0.001

BMI

< 29.7

12

-2.30 (-8.82, 4.23)

0.490

99.6

< 0.001

≥ 29.7

12

-1.98 (-9.80, 5.83)

0.619

93.9

< 0.001

Unknown

2

-0.36 (-4.70, 3.99)

0.783

0.00

0.601

Geographical region

Asia

17

-2.52 (-9.87, 4.82)

0.501

99.0

< 0.001

Australia

1

0.14 (-0.06, 0.34)

0.180

-

-

Europe

3

-0.56 (-9.44, 8.32)

0.901

63.1

0.066

Americas

5

-2.79 (-15.32, 9.74)

0.663

94.4

< 0.001

Quality assessment

Good

1

23.90 (0.95, 46.85)

0.041

-

-

Fair

15

-0.75 (-6.35, 4.86)

0.795

99.5

< 0.001

Weak

10

-5.42 (-13.21, 2.37)

0.173

91.0

< 0.001

Publication year of article

< 2017

13

-3.33 (-7.50, 0.85)

0.118

89.4

< 0.001

≥ 2017

13

-0.09 (-8.78, 8.59)

0.983

99.3

< 0.001